Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection

被引:0
|
作者
Marina Rankovic
Nevena Jeremic
Ivan Srejovic
Katarina Radonjic
Aleksandra Stojanovic
Milos Glisic
Stefani Bolevich
Sergey Bolevich
Vladimir Jakovljevic
机构
[1] University of Kragujevac,Department of Pharmacy, Faculty of Medical Sciences
[2] University of Kragujevac,Department of Physiology, Faculty of Medical Sciences
[3] 1st Moscow State Medical University IM Sechenov,Department of Pathophysiology
[4] 1st Moscow State Medical University IM Sechenov,Department of Human Pathology
来源
Heart Failure Reviews | 2021年 / 26卷
关键词
DPP-4 inhibitors; Diabetes; Ischaemic-reperfusion injury; Cardioprotection;
D O I
暂无
中图分类号
学科分类号
摘要
Previous studies have demonstrated that individuals with type 2 diabetes mellitus (T2DM) have a two- to fourfold propensity to develop cardiovascular disease (CVD) than nondiabetic population, making CVD a major cause of death and disability among people with T2DM. The present treatment options for management of diabetes propose the earlier and more frequent use of new antidiabetic drugs that could control hyperglycaemia and reduce the risk of cardiovascular events. Findings from basic and clinical studies pointed out DPP-4 inhibitors as potentially novel pharmacological tools for cardioprotection. There is a growing body of evidence suggesting that these drugs have ability to protect the heart against acute ischaemia-reperfusion injury as well as reduce the size of infarction. Consequently, the prevention of degradation of the incretin hormones by the use of DPP-4 inhibitors represents a new strategy in the treatment of patients with T2DM and reduction of CV events in these patients. Here, we discuss the cardioprotective effects of DPP-4 inhibitors as well as proposed pathways that these hypoglycaemic agents target in the cardiovascular system.
引用
收藏
页码:437 / 450
页数:13
相关论文
共 50 条
  • [41] Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
    Scheen, Andre
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (04) : 545 - 557
  • [42] Determination of Dipeptidyl Peptidase-4 Inhibitors by Spectrophotometric and Chromatographic Methods
    Deshpande, P.B. (padmanabh77@yahoo.co.in), 1600, Pleiades journals (73):
  • [43] Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: decongesting the matter
    Vaduganathan, Muthiah
    Bhatt, Deepak L.
    EUROPEAN HEART JOURNAL, 2015, 36 (24) : 1497 - 1498
  • [44] Interstitial pneumonia during administration of dipeptidyl peptidase-4 inhibitors
    Tagaya, Yuko
    Okada, Shuichi
    Hisada, Takashi
    Niijima, Yawara
    Yamada, Masanobu
    JOURNAL OF DIABETES, 2016, 8 (03) : 442 - 442
  • [45] Potential role of dipeptidyl peptidase-4 inhibitors in atrial fibrillation
    Zhang, Xiaowei
    Zhang, Zhiwei
    Li, Mingzhen
    Li, Guangping
    Liu, Tong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 207 : 46 - 47
  • [46] Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?
    Monami M.
    Mannucci E.
    Current Cardiovascular Risk Reports, 2015, 9 (8)
  • [47] Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications
    Ahren, Bo
    DIABETES CARE, 2007, 30 (06) : 1344 - 1350
  • [48] Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
    Mulvihill, Erin E.
    Drucker, Daniel J.
    ENDOCRINE REVIEWS, 2014, 35 (06) : 992 - 1019
  • [49] DIPEPTIDYL PEPTIDASE-4 INHIBITORS, SULPHONYLUREAS, AND HYPOGLYCAEMIA Under-representation of frail older people in meta-analysis of dipeptidyl peptidase-4 inhibitors and hypoglycaemia
    Tufan, Fatih
    Soyluk, Ozlem
    Bahat, Gulistan
    Karan, Mehmet Akif
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 353
  • [50] Erratum to: Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
    Larry K. Golightly
    Caitlin C. Drayna
    Michael T. McDermott
    Clinical Pharmacokinetics, 2012, 51 : 831 - 831